Abstract
The radionuclide [99mTc]Tc-(HE)3-G3 is safe, well tolerated, and enables differentiation between HER2-positive and HER2-negative breast tumours, according to a first-in-human study presented by Olga Bragina (Tomsk National Research Medical Center, Tomsk, Russia). Patients with clinically confirmed HER2-positive or HER2-negative primary breast cancer were given [99mTc]Tc-(HE)3-G3 at a protein dose of 1000 μg (n=9), 2000 μg (n=10), or 3000 μg (n=9). No side-effects were noted during 7 days of post-injection observation. Visualisation of tumours using planar scintigraphy and single-photon-emission CT imaging was possible 2 h after injection, and the tumour-to-contralateral site ratio for HER2-positive breast tumours was significantly higher than the ratio for HER2-negative breast tumours (p<0·05).
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
